Vanda Pharmaceuticals Inc. (VNDA)
USD 4.15
(-5.03%)
USD 4.15
(-5.03%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 103.53 Million USD | -3.29% |
| 2022 | 107.04 Million USD | 20.46% |
| 2021 | 88.86 Million USD | 10.82% |
| 2020 | 80.19 Million USD | 10.15% |
| 2019 | 72.8 Million USD | 28.38% |
| 2018 | 56.7 Million USD | -23.41% |
| 2017 | 74.03 Million USD | -6.33% |
| 2016 | 79.04 Million USD | -1.22% |
| 2015 | 80.02 Million USD | 635.03% |
| 2014 | 10.88 Million USD | -89.03% |
| 2013 | 99.22 Million USD | -20.96% |
| 2012 | 125.54 Million USD | -15.82% |
| 2011 | 149.14 Million USD | -14.96% |
| 2010 | 175.37 Million USD | -13.48% |
| 2009 | 202.68 Million USD | 5078.99% |
| 2008 | 3.91 Million USD | -70.2% |
| 2007 | 13.13 Million USD | 38.18% |
| 2006 | 9.5 Million USD | 86.78% |
| 2005 | 5.08 Million USD | 181.31% |
| 2004 | 1.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 108.85 Million USD | 0.15% |
| 2024 Q1 | 108.68 Million USD | 4.98% |
| 2023 Q4 | 103.53 Million USD | 5.1% |
| 2023 Q2 | 101.78 Million USD | -6.44% |
| 2023 Q1 | 108.79 Million USD | 1.63% |
| 2023 FY | 103.53 Million USD | -3.29% |
| 2023 Q3 | 98.5 Million USD | -3.22% |
| 2022 FY | 107.04 Million USD | 20.46% |
| 2022 Q3 | 106.13 Million USD | 5.55% |
| 2022 Q4 | 107.04 Million USD | 0.86% |
| 2022 Q1 | 101.43 Million USD | 14.15% |
| 2022 Q2 | 100.55 Million USD | -0.87% |
| 2021 Q1 | 75.56 Million USD | -5.77% |
| 2021 Q4 | 88.86 Million USD | 2.8% |
| 2021 FY | 88.86 Million USD | 10.82% |
| 2021 Q2 | 86.42 Million USD | 14.37% |
| 2021 Q3 | 86.44 Million USD | 0.02% |
| 2020 Q1 | 72.13 Million USD | -0.91% |
| 2020 Q3 | 75.33 Million USD | 0.38% |
| 2020 Q4 | 80.19 Million USD | 6.45% |
| 2020 Q2 | 75.04 Million USD | 4.03% |
| 2020 FY | 80.19 Million USD | 10.15% |
| 2019 FY | 72.8 Million USD | 28.38% |
| 2019 Q2 | 75.78 Million USD | 4.16% |
| 2019 Q3 | 73.54 Million USD | -2.96% |
| 2019 Q4 | 72.8 Million USD | -1.0% |
| 2019 Q1 | 72.76 Million USD | 28.31% |
| 2018 Q4 | 56.7 Million USD | 12.25% |
| 2018 Q3 | 50.52 Million USD | -2.2% |
| 2018 Q2 | 51.65 Million USD | -32.19% |
| 2018 Q1 | 76.17 Million USD | 2.88% |
| 2018 FY | 56.7 Million USD | -23.41% |
| 2017 Q1 | 76.57 Million USD | -3.12% |
| 2017 Q3 | 75.23 Million USD | -5.07% |
| 2017 Q2 | 79.25 Million USD | 3.49% |
| 2017 Q4 | 74.03 Million USD | -1.59% |
| 2017 FY | 74.03 Million USD | -6.33% |
| 2016 Q4 | 79.04 Million USD | -0.3% |
| 2016 FY | 79.04 Million USD | -1.22% |
| 2016 Q3 | 79.27 Million USD | -1.42% |
| 2016 Q2 | 80.42 Million USD | -3.95% |
| 2016 Q1 | 83.72 Million USD | 4.63% |
| 2015 Q1 | 61.16 Million USD | 461.84% |
| 2015 Q4 | 80.02 Million USD | 7.26% |
| 2015 Q2 | 73.94 Million USD | 20.89% |
| 2015 FY | 80.02 Million USD | 635.03% |
| 2015 Q3 | 74.6 Million USD | 0.89% |
| 2014 Q1 | 99.99 Million USD | 0.78% |
| 2014 FY | 10.88 Million USD | -89.03% |
| 2014 Q2 | 85.28 Million USD | -14.71% |
| 2014 Q4 | 10.88 Million USD | -86.06% |
| 2014 Q3 | 78.11 Million USD | -8.41% |
| 2013 Q3 | 105.08 Million USD | -6.11% |
| 2013 FY | 99.22 Million USD | -20.96% |
| 2013 Q4 | 99.22 Million USD | -5.58% |
| 2013 Q2 | 111.92 Million USD | -5.67% |
| 2013 Q1 | 118.65 Million USD | -5.48% |
| 2012 FY | 125.54 Million USD | -15.82% |
| 2012 Q1 | 145.67 Million USD | -2.32% |
| 2012 Q2 | 140.75 Million USD | -3.38% |
| 2012 Q3 | 134.45 Million USD | -4.47% |
| 2012 Q4 | 125.54 Million USD | -6.63% |
| 2011 Q1 | 169.76 Million USD | -3.2% |
| 2011 Q4 | 149.14 Million USD | -5.64% |
| 2011 Q3 | 158.05 Million USD | -3.57% |
| 2011 FY | 149.14 Million USD | -14.96% |
| 2011 Q2 | 163.9 Million USD | -3.45% |
| 2010 Q2 | 192.83 Million USD | -3.24% |
| 2010 Q3 | 183.19 Million USD | -5.0% |
| 2010 FY | 175.37 Million USD | -13.48% |
| 2010 Q4 | 175.37 Million USD | -4.27% |
| 2010 Q1 | 199.28 Million USD | -1.67% |
| 2009 Q3 | 8.89 Million USD | -24.83% |
| 2009 FY | 202.68 Million USD | 5078.99% |
| 2009 Q2 | 11.83 Million USD | 197.08% |
| 2009 Q1 | 3.98 Million USD | 1.81% |
| 2009 Q4 | 202.68 Million USD | 2177.83% |
| 2008 Q4 | 3.91 Million USD | -12.61% |
| 2008 Q1 | 10.74 Million USD | -18.21% |
| 2008 Q3 | 4.47 Million USD | -55.98% |
| 2008 FY | 3.91 Million USD | -70.2% |
| 2008 Q2 | 10.17 Million USD | -5.28% |
| 2007 Q4 | 13.13 Million USD | -15.8% |
| 2007 Q2 | 9.28 Million USD | 26.12% |
| 2007 Q1 | 7.36 Million USD | -22.53% |
| 2007 FY | 13.13 Million USD | 38.18% |
| 2007 Q3 | 15.59 Million USD | 67.95% |
| 2006 Q1 | 11.12 Million USD | 118.67% |
| 2006 FY | 9.5 Million USD | 86.78% |
| 2006 Q3 | 10.33 Million USD | -39.94% |
| 2006 Q2 | 17.2 Million USD | 54.6% |
| 2006 Q4 | 9.5 Million USD | -8.01% |
| 2005 Q4 | 5.08 Million USD | 0.0% |
| 2005 FY | 5.08 Million USD | 181.31% |
| 2004 FY | 1.8 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 69.167% |
| Alkermes plc | 933.53 Million USD | 88.91% |
| Agenus Inc. | 462.29 Million USD | 77.605% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 97.444% |
| Aptorum Group Limited | 5.25 Million USD | -1869.472% |
| Ardelyx, Inc. | 130.76 Million USD | 20.826% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 78.359% |
| Bicycle Therapeutics plc | 224.41 Million USD | 53.866% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | 20.49% |
| ChromaDex Corporation | 26.5 Million USD | -290.561% |
| Chimerix, Inc. | 19.74 Million USD | -424.335% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -194.311% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -42.668% |
| CRISPR Therapeutics AG | 346.76 Million USD | 70.144% |
| Precision BioSciences, Inc. | 140.92 Million USD | 26.533% |
| Dyadic International, Inc. | 2.34 Million USD | -4323.128% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -536.598% |
| Fortress Biotech, Inc. | 165.93 Million USD | 37.61% |
| Lantern Pharma Inc. | 2.73 Million USD | -3678.906% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -44.838% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -2833.921% |
| Incyte Corporation | 1.59 Billion USD | 93.498% |
| IO Biotech, Inc. | 17.55 Million USD | -489.713% |
| Jaguar Health, Inc. | 45.86 Million USD | -125.723% |
| Novavax, Inc. | 2.57 Billion USD | 95.975% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -187.121% |
| Opthea Limited | 264.6 Million USD | 60.873% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | 20.792% |
| ContextLogic Inc. | 206 Million USD | 49.743% |
| MiMedx Group, Inc. | 96.33 Million USD | -7.474% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -115.589% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -2833.786% |
| NextCure, Inc. | 14.99 Million USD | -590.338% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -2461.356% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -1450.547% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -121.507% |
| Vaxcyte, Inc. | 167.44 Million USD | 38.172% |
| PDS Biotechnology Corporation | 33.25 Million USD | -211.283% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | 55.985% |
| Pharming Group N.V. | 244.07 Million USD | 57.582% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -768.395% |
| Avidity Biosciences, Inc. | 127.79 Million USD | 18.985% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1466.908% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -1466.908% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -25.593% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -1458.483% |
| Acelyrin, Inc. | 86.35 Million USD | -19.892% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -7868.499% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -620.008% |
| Summit Therapeutics Inc. | 125.25 Million USD | 17.346% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -992.204% |
| Senti Biosciences, Inc. | 52.57 Million USD | -96.934% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -50.53% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | 31.669% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -5192.945% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -7651.781% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | 54.358% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -1005.263% |
| Wave Life Sciences Ltd. | 227.44 Million USD | 54.481% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 79.064% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -848.598% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -276.322% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -755.288% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 78.724% |
| Immix Biopharma, Inc. | 3.72 Million USD | -2681.731% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -173.802% |
| MEI Pharma, Inc. | 8.35 Million USD | -1139.138% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -256.815% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 70.214% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | 29.025% |
| Fortress Biotech, Inc. | 165.93 Million USD | 37.61% |
| Precigen, Inc. | 41.64 Million USD | -148.607% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -107.35% |
| AlloVir, Inc. | 45.01 Million USD | -129.99% |
| C4 Therapeutics, Inc. | 130.33 Million USD | 20.567% |
| Fate Therapeutics, Inc. | 137.8 Million USD | 24.869% |
| ImmuCell Corporation | 18.81 Million USD | -450.252% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -266.789% |
| Onconetix, Inc. | 23.18 Million USD | -346.618% |
| PureTech Health plc | 125.58 Million USD | 17.56% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -1056.76% |
| Elevation Oncology, Inc. | 34.28 Million USD | -201.995% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -4134.356% |
| Seer, Inc. | 39.36 Million USD | -163.0% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -67.432% |
| Innoviva, Inc. | 568.55 Million USD | 81.791% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -280.234% |
| ESSA Pharma Inc. | 3.49 Million USD | -2862.172% |
| GlycoMimetics, Inc. | 6.9 Million USD | -1399.984% |
| GT Biopharma, Inc. | 6.63 Million USD | -1460.832% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 60.842% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 61.978% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -23.212% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -959.239% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -281.059% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -3109.463% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -40.347% |
| Aptose Biosciences Inc. | 15.8 Million USD | -554.893% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -837.798% |
| Soligenix, Inc. | 7.27 Million USD | -1323.112% |
| Century Therapeutics, Inc. | 175.94 Million USD | 41.156% |
| Kura Oncology, Inc. | 51.66 Million USD | -100.399% |
| TScan Therapeutics, Inc. | 121.28 Million USD | 14.637% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -2404.96% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -1465.35% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 59.014% |
| Autolus Therapeutics plc | 263.9 Million USD | 60.77% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -887.693% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -16.508% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -120.751% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 70.659% |
| GRI Bio, Inc. | 2.69 Million USD | -3738.71% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -12688.033% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -232.99% |
| IGM Biosciences, Inc. | 220.17 Million USD | 52.979% |
| INmune Bio, Inc. | 18.86 Million USD | -448.881% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 59.634% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -288.6% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -3708.482% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -3056.146% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -77.111% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -7.665% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 60.893% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 87.421% |
| Verastem, Inc. | 71.18 Million USD | -45.438% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -110.53% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -168.365% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -111.579% |
| Histogen Inc. | 5.69 Million USD | -1717.272% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -2260.678% |
| Surrozen, Inc. | 8.14 Million USD | -1171.087% |
| Organovo Holdings, Inc. | 2.74 Million USD | -3667.467% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -32886.255% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -84.119% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -526.999% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -102.591% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -12420.635% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | 18.303% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -857.406% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | 31.387% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -3870.706% |
| Apollomics, Inc. | 14.15 Million USD | -631.506% |
| Amarin Corporation plc | 279.58 Million USD | 62.97% |
| Mesoblast Limited | 188.79 Million USD | 45.164% |
| Turnstone Biologics Corp. | 14.14 Million USD | -631.764% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | 42.734% |
| Synaptogenix, Inc. | 5.52 Million USD | -1772.332% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -1457.31% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | 39.139% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1109.859% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -5791.113% |
| Exelixis, Inc. | 678.44 Million USD | 84.74% |
| Better Therapeutics, Inc. | 23.84 Million USD | -334.234% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | 36.89% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 82.577% |
| NLS Pharmaceutics AG | 10.68 Million USD | -869.364% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -6276.508% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -165.959% |
| Gritstone bio, Inc. | 125.91 Million USD | 17.78% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -605.437% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -1934.537% |
| Avid Bioservices, Inc. | 275.66 Million USD | 62.444% |
| Insmed Incorporated | 1.66 Billion USD | 93.77% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -1245.59% |
| MediWound Ltd. | 27.18 Million USD | -280.807% |
| OmniAb, Inc. | 87.4 Million USD | -18.455% |
| Alector, Inc. | 487.66 Million USD | 78.77% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 74.339% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -461.9% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -169.799% |
| Zai Lab Limited | 240.17 Million USD | 56.894% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 83.568% |
| Aura Biosciences, Inc. | 29.22 Million USD | -254.227% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -8.891% |
| Immunic, Inc. | 25.36 Million USD | -308.113% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -49.532% |
| Veracyte, Inc. | 93.71 Million USD | -10.469% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -3856.551% |
| FibroGen, Inc. | 585.72 Million USD | 82.325% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -495.582% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -15752.673% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -1730.621% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 98.648% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -1162.869% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -23.218% |
| TG Therapeutics, Inc. | 169.08 Million USD | 38.77% |
| Galecto, Inc. | 5.89 Million USD | -1655.936% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -1149.759% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 96.046% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -259.205% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -720.3% |
| XBiotech Inc. | 8.39 Million USD | -1132.94% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -605.437% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -94.678% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 71.488% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -285.099% |
| Theravance Biopharma, Inc. | 169 Million USD | 38.741% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 91.483% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 79.312% |
| Vaxxinity, Inc. | 30.94 Million USD | -234.572% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 89.354% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -1616.6% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 86.108% |
| NexImmune, Inc. | 5.08 Million USD | -1936.296% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -27776.056% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -3266.996% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.543% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -1908.719% |
| Scopus BioPharma Inc. | 7.45 Million USD | -1288.838% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -293.74% |
| Ainos, Inc. | 7.39 Million USD | -1300.147% |
| Pluri Inc. | 34.11 Million USD | -203.5% |
| Prothena Corporation plc | 135.01 Million USD | 23.321% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 57.413% |
| Celularity Inc. | 102.92 Million USD | -0.584% |
| Rallybio Corporation | 9.43 Million USD | -997.181% |
| Cue Biopharma, Inc. | 24.44 Million USD | -323.522% |
| MeiraGTx Holdings plc | 319.99 Million USD | 67.646% |
| Omeros Corporation | 403.25 Million USD | 74.326% |
| Humacyte, Inc. | 114.67 Million USD | 9.72% |
| Immunocore Holdings plc | 228.15 Million USD | 54.624% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -2023.692% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -34.91% |
| Blueprint Medicines Corporation | 918.64 Million USD | 88.73% |
| CalciMedica, Inc. | 4.02 Million USD | -2470.258% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -493.227% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | 32.835% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -20.64% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 62.731% |
| Pulmatrix, Inc. | 15.96 Million USD | -548.562% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -556.375% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -320.751% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 58.721% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -103.855% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 91.448% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -225.74% |
| Nutriband Inc. | 1.07 Million USD | -9495.716% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -873.667% |
| Vor Biopharma Inc. | 59.1 Million USD | -75.166% |
| Roivant Sciences Ltd. | 773.95 Million USD | 86.623% |
| Evogene Ltd. | 17.99 Million USD | -475.486% |
| ProKidney Corp. | 29.21 Million USD | -254.361% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -43.834% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -14585.461% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 94.519% |
| CorMedix Inc. | 11.91 Million USD | -768.72% |
| BioLineRx Ltd. | 50.7 Million USD | -104.193% |
| Tango Therapeutics, Inc. | 149.45 Million USD | 30.73% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -17.061% |
| Atai Life Sciences N.V. | 49.16 Million USD | -110.589% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -232.335% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -476.383% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | 16.934% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -1731.093% |
| MediciNova, Inc. | 3.89 Million USD | -2560.377% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -466.388% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -6782.541% |
| GeoVax Labs, Inc. | 3.51 Million USD | -2841.293% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 73.939% |
| Biomea Fusion, Inc. | 30.69 Million USD | -237.341% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 96.196% |
| Mereo BioPharma Group plc | 15.96 Million USD | -548.603% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -231.816% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -76.419% |
| Absci Corporation | 58.3 Million USD | -77.569% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -443.522% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -222.906% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -40.304% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -18.343% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -206.574% |
| Allakos Inc. | 74.79 Million USD | -38.422% |
| Imunon, Inc. | 8.53 Million USD | -1113.656% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -360.113% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 9.826% |
| BioAtla, Inc. | 48.98 Million USD | -111.346% |
| NLS Pharmaceutics AG | 10.68 Million USD | -869.364% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -3625.441% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | 20.73% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -628.315% |
| XOMA Corporation | 145.58 Million USD | 28.884% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -207.53% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -50.569% |
| aTyr Pharma, Inc. | 31.59 Million USD | -227.658% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -67.462% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -130.246% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -113.896% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -3507.317% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -1169.058% |
| Akari Therapeutics, Plc | 4.58 Million USD | -2158.508% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -483.822% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 93.723% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -25532.075% |
| UroGen Pharma Ltd. | 243.52 Million USD | 57.487% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 67.756% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -3648.971% |
| Orgenesis Inc. | 35.53 Million USD | -191.347% |
| Entera Bio Ltd. | 1.37 Million USD | -7407.614% |
| GH Research PLC | 6.7 Million USD | -1444.993% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -1422.5% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -449.931% |
| Xencor, Inc. | 283.55 Million USD | 63.489% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -3367.558% |
| Replimune Group, Inc. | 113.21 Million USD | 8.554% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -2655.564% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -25532.075% |
| Portage Biotech Inc. | 4.45 Million USD | -2226.517% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -6782.541% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -349.154% |
| OncoCyte Corporation | 49.29 Million USD | -110.009% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -2402.656% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -12882.079% |
| Purple Biotech Ltd. | 10 Million USD | -934.783% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -1689.319% |
| scPharmaceuticals Inc. | 57.26 Million USD | -80.804% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -735.727% |
| HilleVax, Inc. | 78.9 Million USD | -31.202% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -1950.099% |
| Tharimmune, Inc. | 1.81 Million USD | -5603.988% |
| Genprex, Inc. | 3.25 Million USD | -3081.419% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -281.762% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -1877.273% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -50157.282% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -28774.795% |
| OKYO Pharma Limited | 7.42 Million USD | -1295.124% |
| Savara Inc. | 37.19 Million USD | -178.366% |
| Curis, Inc. | 57.61 Million USD | -79.702% |
| Daré Bioscience, Inc. | 26.32 Million USD | -293.204% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -164.109% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -7069.668% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -397.286% |
| BeiGene, Ltd. | 2.23 Billion USD | 95.365% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -386.289% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 60.545% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -386.65% |
| Erasca, Inc. | 78.61 Million USD | -31.699% |
| bluebird bio, Inc. | 424.62 Million USD | 75.618% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -15700.028% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 94.522% |
| DBV Technologies S.A. | 42.8 Million USD | -141.893% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -15700.028% |
| Moderna, Inc. | 4.57 Billion USD | 97.736% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -1380.057% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -6151.812% |
| Molecular Templates, Inc. | 31.17 Million USD | -232.136% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -506.503% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 82.396% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | 16.847% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -277.337% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -183.986% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -86.088% |
| MacroGenics, Inc. | 154.2 Million USD | 32.863% |
| RenovoRx, Inc. | 4.46 Million USD | -2218.182% |
| Adicet Bio, Inc. | 37.12 Million USD | -178.906% |
| Prime Medicine, Inc. | 60.78 Million USD | -70.336% |
| Aditxt, Inc. | 28.53 Million USD | -262.861% |
| Adagene Inc. | 45.16 Million USD | -129.204% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -57193.54% |
| Quantum-Si incorporated | 26.63 Million USD | -288.757% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 85.158% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -3302.863% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | 9.943% |
| SciSparc Ltd. | 1.59 Million USD | -6390.909% |
| Vericel Corporation | 127.7 Million USD | 18.93% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -1760.413% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -21.289% |
| Generation Bio Co. | 171.63 Million USD | 39.678% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -796.364% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -147.496% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 59.03% |
| Invivyd, Inc. | 51.71 Million USD | -100.201% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -12.561% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -1491.484% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -37.133% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -10040.059% |
| 2seventy bio, Inc. | 310.12 Million USD | 66.617% |
| ADMA Biologics, Inc. | 193.97 Million USD | 46.627% |
| Clene Inc. | 38.95 Million USD | -165.795% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -186.526% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 59.712% |
| GeoVax Labs, Inc. | 3.51 Million USD | -2841.293% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | 45.586% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -750.024% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | 47.797% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -748.968% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -115.19% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -95.927% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 72.008% |
| Evaxion Biotech A/S | 17.61 Million USD | -487.655% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | 35.667% |
| Verve Therapeutics, Inc. | 153.18 Million USD | 32.415% |
| Trevena, Inc. | 48.26 Million USD | -114.517% |
| Surrozen, Inc. | 8.14 Million USD | -1171.087% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -379.417% |
| Cingulate Inc. | 10.36 Million USD | -899.241% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -3664.727% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -177.62% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -2786.642% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -687.3% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 67.361% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -316.636% |
| Clearmind Medicine Inc. | 3.61 Million USD | -2767.861% |
| Kronos Bio, Inc. | 54.2 Million USD | -91.011% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -120.075% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -354.882% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -415.819% |
| Statera Biopharma, Inc. | 22.67 Million USD | -356.553% |
| ImmunityBio, Inc. | 1.09 Billion USD | 90.505% |
| Korro Bio, Inc. | 51.75 Million USD | -100.05% |
| Kineta, Inc. | 7.22 Million USD | -1333.536% |
| BioVie Inc. | 9.7 Million USD | -967.085% |
| Codexis, Inc. | 49.94 Million USD | -107.284% |
| Celularity Inc. | 102.92 Million USD | -0.584% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -7.567% |
| Celcuity Inc. | 51.45 Million USD | -101.224% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -29891.831% |
| Cibus, Inc. | 206.11 Million USD | 49.771% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -143.743% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -293.067% |
| IN8bio, Inc. | 8.77 Million USD | -1080.233% |
| Kodiak Sciences Inc. | 213.59 Million USD | 51.529% |
| Annexon, Inc. | 47.11 Million USD | -119.725% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -15.623% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -7.427% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -656.301% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 96.023% |
| Eyenovia, Inc. | 19.78 Million USD | -423.4% |
| Puma Biotechnology, Inc. | 177.08 Million USD | 41.537% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1247.871% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -329.603% |
| Arcellx, Inc. | 339.75 Million USD | 69.528% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -770.146% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 57.836% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -982.61% |
| Moolec Science SA | 13.94 Million USD | -642.398% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -139.919% |
| Geron Corporation | 146.12 Million USD | 29.151% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -104.88% |
| Royalty Pharma plc | 6.29 Billion USD | 98.356% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -160.283% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -35065.724% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -4108.054% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | 45.267% |
| Humacyte, Inc. | 114.67 Million USD | 9.72% |
| Structure Therapeutics Inc. | 29.05 Million USD | -256.373% |
| 89bio, Inc. | 59.96 Million USD | -72.656% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -291.225% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -8556.355% |
| Genelux Corporation | 8.42 Million USD | -1129.572% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -1410.064% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | 24.053% |
| Notable Labs, Ltd. | 4.42 Million USD | -2238.604% |
| Liquidia Corporation | 73.13 Million USD | -41.554% |
| Mustang Bio, Inc. | 17.61 Million USD | -487.604% |
| Immunovant, Inc. | 48.95 Million USD | -111.48% |
| Quantum-Si incorporated | 26.63 Million USD | -288.757% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -169.729% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -3236.449% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -40.169% |
| Acasti Pharma Inc. | 11.55 Million USD | -795.821% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -357.941% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -3708.482% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -180.744% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -7496.625% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -1598.327% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -316.871% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -346.558% |
| PepGen Inc. | 34.63 Million USD | -198.952% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -752.52% |
| United Therapeutics Corporation | 1.18 Billion USD | 91.243% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -1382.388% |
| Solid Biosciences Inc. | 38.45 Million USD | -169.203% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -1109.859% |
| Immuneering Corporation | 12 Million USD | -762.15% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -32886.255% |
| Silo Pharma, Inc. | 1.56 Million USD | -6497.335% |
| Belite Bio, Inc | 4.21 Million USD | -2358.561% |
| XOMA Corporation | 145.58 Million USD | 28.884% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -4164.003% |
| Bionomics Limited | 10.15 Million USD | -919.124% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -381.737% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -351.84% |
| uniQure N.V. | 624.01 Million USD | 83.409% |
| Cassava Sciences, Inc. | 14.19 Million USD | -629.341% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -57193.54% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | 39.166% |
| Forte Biosciences, Inc. | 3.66 Million USD | -2724.059% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -39630.144% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -1434.46% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -1247.871% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -495.582% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -879.656% |
| Altimmune, Inc. | 16.54 Million USD | -525.899% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 83.24% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -351.84% |
| Compugen Ltd. | 55.77 Million USD | -85.621% |
| Peak Bio, Inc. | 20.75 Million USD | -398.859% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | 6.276% |
| Benitec Biopharma Inc. | 4.96 Million USD | -1986.457% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | 34.41% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -37.72% |
| Zura Bio Limited | 21.29 Million USD | -386.239% |
| PolyPid Ltd. | 17.46 Million USD | -492.684% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | 7.891% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -37.72% |
| Instil Bio, Inc. | 99.8 Million USD | -3.736% |
| argenx SE | 444.95 Million USD | 76.732% |
| Immunome, Inc. | 28.65 Million USD | -261.26% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -1141.814% |
| Verona Pharma plc | 58.84 Million USD | -75.949% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -615.332% |
| Shattuck Labs, Inc. | 14.85 Million USD | -596.749% |
| CervoMed Inc. | 2.59 Million USD | -3888.447% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -2024.128% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -712.893% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -882.724% |
| Moolec Science SA | 13.94 Million USD | -642.398% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -4317.744% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -86.221% |
| AnaptysBio, Inc. | 364.28 Million USD | 71.58% |
| Design Therapeutics, Inc. | 11.95 Million USD | -765.925% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -716.225% |
| NeurAxis, Inc. | 1.91 Million USD | -5312.657% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -165.953% |
| Lumos Pharma, Inc. | 13.33 Million USD | -676.494% |
| Achilles Therapeutics plc | 19.08 Million USD | -442.411% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -615.332% |
| 180 Life Sciences Corp. | 5.38 Million USD | -1821.774% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -338.91% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -354.882% |
| Nutriband Inc. | 1.07 Million USD | -9495.716% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -238.355% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -613.459% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 74.2% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -218.819% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -693.388% |
| Palisade Bio, Inc. | 2.73 Million USD | -3679.847% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -1870.874% |
| Beam Therapeutics Inc. | 478.38 Million USD | 78.358% |
| Neurogene Inc. | 36.54 Million USD | -183.264% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 73.984% |
| AEON Biopharma, Inc. | 159.88 Million USD | 35.249% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -117.272% |
| Sesen Bio, Inc. | 30.98 Million USD | -234.14% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -298.79% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -1261.84% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 47.108% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | 46.094% |
| Athira Pharma, Inc. | 30.05 Million USD | -244.446% |
| Vaccinex, Inc. | 5.94 Million USD | -1642.343% |
| HCW Biologics Inc. | 15.05 Million USD | -587.818% |
| XOMA Corporation | 145.58 Million USD | 28.884% |
| Nektar Therapeutics | 267.04 Million USD | 61.231% |
| Arvinas, Inc. | 644.6 Million USD | 83.939% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -483.822% |
| Merus N.V. | 102.15 Million USD | -1.35% |
| Omega Therapeutics, Inc. | 146.35 Million USD | 29.259% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -8.841% |
| Rezolute, Inc. | 11.73 Million USD | -782.308% |
| Clene Inc. | 38.95 Million USD | -165.795% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -3535.974% |
| BeyondSpring Inc. | 48.26 Million USD | -114.485% |
| Synlogic, Inc. | 32.89 Million USD | -214.729% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -608.479% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -6235.985% |
| Peak Bio, Inc. | 20.75 Million USD | -398.859% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -63.145% |
| Krystal Biotech, Inc. | 39.71 Million USD | -160.689% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 72.513% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -3.978% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -23825.07% |
| MannKind Corporation | 721.36 Million USD | 85.648% |
| Ikena Oncology, Inc. | 22.33 Million USD | -363.533% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -4863.087% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -0.916% |
| Gossamer Bio, Inc. | 249.14 Million USD | 58.446% |
| CohBar, Inc. | 1.03 Million USD | -9916.079% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -868.566% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -443.522% |
| Legend Biotech Corporation | 589.93 Million USD | 82.451% |
| Mural Oncology plc | 37.92 Million USD | -172.965% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 21.944% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -4410.459% |
| Disc Medicine, Inc. | 22.87 Million USD | -352.59% |
| Champions Oncology, Inc. | 28.03 Million USD | -269.288% |
| REGENXBIO Inc. | 262.22 Million USD | 60.519% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -2981.844% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -725.993% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -670.793% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -388.234% |
| Vaxart, Inc. | 34.02 Million USD | -204.276% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -407.767% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -262.857% |
| Cellectis S.A. | 249.57 Million USD | 58.517% |
| Longeveron Inc. | 5.33 Million USD | -1839.854% |
| Repare Therapeutics Inc. | 41.81 Million USD | -147.567% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 95.696% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -71.498% |
| Revolution Medicines, Inc. | 262.39 Million USD | 60.545% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -4813.621% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -1100.209% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -777.299% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -637.236% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -4713.11% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.99% |
| Denali Therapeutics Inc. | 122.96 Million USD | 15.804% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -1760.413% |
| Veru Inc. | 32.81 Million USD | -215.518% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -1407.206% |
| Cingulate Inc. | 10.36 Million USD | -899.241% |
| Passage Bio, Inc. | 39.26 Million USD | -163.69% |
| Context Therapeutics Inc. | 4.19 Million USD | -2369.872% |
| Exicure, Inc. | 8.54 Million USD | -1111.019% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -250.854% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -887.316% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -369.716% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | 36.479% |
| Nuvalent, Inc. | 31.82 Million USD | -225.331% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -1527.414% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -64.276% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -475.167% |
| OmniAb, Inc. | 87.4 Million USD | -18.455% |
| Anew Medical, Inc. | 8.24 Million USD | -1156.158% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -170.39% |
| Lipocine Inc. | 2.63 Million USD | -3834.065% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -294.07% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -157.46% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -288.6% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -20.169% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -1816.867% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -25.116% |
| Ocugen, Inc. | 23.98 Million USD | -331.681% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -123.091% |
| Q32 Bio Inc. | 233.12 Million USD | 55.591% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -1041.959% |
| Alumis Inc. Common Stock | 53.5 Million USD | -93.507% |
| Equillium, Inc. | 27.95 Million USD | -270.319% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | 49.887% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -1739.989% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -1588.09% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 34.194% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -49.108% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -937.978% |
| Dominari Holdings Inc. | 4.63 Million USD | -2133.657% |
| Edesa Biotech, Inc. | 1.84 Million USD | -5521.629% |
| vTv Therapeutics Inc. | 29.56 Million USD | -250.154% |
| Bio-Techne Corporation | 744.34 Million USD | 86.091% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 17.898% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 69.944% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -155.157% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -257.53% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -12.094% |
| Nkarta, Inc. | 105.6 Million USD | 1.96% |
| BioCardia, Inc. | 4.59 Million USD | -2155.556% |
| Iterum Therapeutics plc | 32.66 Million USD | -216.974% |